Hosted on MSN
TriSalus reaffirms 50% revenue growth target while advancing TriNav platform and product launches
CEO Mary Szela reported strong third quarter results, highlighting revenue of $11.6 million, a 57% increase year-over-year and 3% sequential growth. She noted continued expansion of the TriNav ...
(RTTNews) - TriSalus Life Sciences, Inc. (TLSI) has unveiled the TriNav FLX Infusion System, a new addition to its TriNav portfolio. The latest system enhances trackability and flexibility, allowing ...
DENVER & SALT LAKE CITY--(BUSINESS WIRE)--TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced its financial results for the fourth quarter and full year ended December 31, 2023, and provided ...
DENVER, November 07, 2024--(BUSINESS WIRE)--TriSalus Life Sciences ® Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), a leader in oncology innovations integrating advanced delivery technology to ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
DENVER--(BUSINESS WIRE)-- TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), which seeks to transform outcomes for patients with solid tumors by integrating our innovative ...
– Data published in Current Medical Research and Opinion provide a comparison of the TriNav Infusion System vs. standard drug delivery and show the ability of TriNav to successfully treat sicker, ...
Good morning, and welcome to TriSalus Science’s Third Quarter 2024 Earnings Conference Call. Currently, all participants are in a listen-only mode. We will facilitate a question-and-answer session ...
, (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, is pleased to announce today ...
CEO Mary Szela framed Q1 as a deliberate build year, saying the company executed a “deliberate realignment and significant expansion of our commercial organization” to “capture the multiyear growth” ...
TriSalus Life Sciences, an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, is pleased to announce the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results